Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
Intensity Therapeutics restarts breast cancer Phase 2 clinical trial
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
HDT Bio Launches Canadian clinical programme for brain cancer treatment
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain
Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma
HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed
GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study